Your browser is no longer supported. Please, upgrade your browser.
Johnson & Johnson
IndexDJIA S&P500 P/E17.57 EPS (ttm)5.70 Insider Own0.01% Shs Outstand2.78B Perf Week-1.52%
Market Cap278.45B Forward P/E15.40 EPS next Y6.50 Insider Trans-29.76% Shs Float2.78B Perf Month-1.06%
Income16.32B PEG2.95 EPS next Q1.52 Inst Own67.50% Short Float0.98% Perf Quarter-3.30%
Sales74.33B P/S3.75 EPS this Y18.50% Inst Trans-0.72% Short Ratio2.99 Perf Half Y-6.58%
Book/sh24.96 P/B4.01 EPS next Y5.09% ROA15.80% Target Price109.27 Perf Year6.02%
Cash/sh11.90 P/C8.42 EPS next 5Y5.96% ROE28.00% 52W Range93.48 - 108.23 Perf YTD-3.56%
Dividend2.80 P/FCF39.84 EPS past 5Y5.30% ROI18.40% 52W High-6.92% Beta0.57
Dividend %2.80% Quick Ratio2.00 Sales past 5Y3.70% Gross Margin69.40% 52W Low7.77% ATR1.47
Employees126500 Current Ratio2.40 Sales Q/Q-0.60% Oper. Margin28.80% RSI (14)49.11 Volatility1.38% 1.39%
OptionableYes Debt/Eq0.27 EPS Q/Q-27.60% Profit Margin28.30% Rel Volume0.41 Prev Close100.14
ShortableYes LT Debt/Eq0.22 EarningsApr 14 BMO Payout36.90% Avg Volume9.15M Price100.75
Recom2.50 SMA20-0.34% SMA50-0.16% SMA200-1.71% Volume2,049,922 Change0.61%
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Dec-12-11Reiterated UBS Buy $72 → $69
Mar-27-15 01:05PM  Google to Develop Robot Surgical Devices in Pact With J&J
12:06PM  Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynns Latest Healthcare Picks at Insider Monkey
10:50AM  J&J, Google To Collaborate On Surgical Robotics at Investor's Business Daily
10:34AM  Johnson & Johnson Teams With Google On Surgery Robot Development
09:40AM  J&J and Google to Jointly Develop Robot-Assisted Surgery Program at Bloomberg
09:30AM  Barron 400 ETF Undergoes Changes - ETF News And Commentary
09:30AM  Google is going to make surgery robots Business Insider
09:28AM  Johnson & Johnson to Webcast Annual Meeting of Shareholders at noodls
09:28AM  Johnson & Johnson Announces Definitive Agreement To Collaborate With Google To Advance Surgical Robotics at noodls
08:36AM  Johnson & Johnson to Webcast Annual Meeting of Shareholders at noodls
08:00AM  Johnson & Johnson to Webcast Annual Meeting of Shareholders PR Newswire
Mar-26-15 04:28PM  MedTech M&As Continue Regardless of Tax Scenarios - Industry Outlook
03:12PM  Pressure's On Senate To Pass 'Doc Fix' In Latest Blow To Fee-For-Service Medicine at Forbes
09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson and Medtronic - Press Releases
Mar-25-15 06:00PM  Cramer: Nasdaq's griddle too hot
05:16PM  Kraft a Menu at the Buffett Buffet With Warrens Latest Deal at Bloomberg
05:16PM  Kraft a Menu at the Buffett Buffet With Warren's Latest Deal
11:11AM  Can Pharma Conquer The Consumer The Way Apple Did? This App Might Help at Forbes
10:59AM  From Snitch Pill to Xbox Sensors, Novartis Goes Digital
10:43AM  Six Standout Startups From This Year's Y Combinator Demo Days The Atlantic
10:06AM  The PharmacyclicsAbbVie Merger: The Basics of Pharmacyclics
08:00AM  Great Stocks That Cost Less Than $10 at Kiplinger
Mar-24-15 07:00PM  From Pills That Snitch to Xbox Sensors, Drugmaker Goes High Tech at Bloomberg
07:00PM  From Pills That Snitch to Xbox Sensors, Drugmaker Goes High Tech
03:58PM  Why PETA Is Now a Domino's and Shake Shack Shareholder at TheStreet
02:53PM  Johnson & Johnson May See EPS Drag Through 2018 at
02:26PM  Stocks to Cure What Ails on World TB Day - Analyst Blog
12:31PM  AstraZeneca to Disclose Trial Data, but how Independent is its Review Panel? at The Wall Street Journal
12:06PM  Could the PharmacyclicsAbbVie Merger Get Competitive?
08:59AM  The Expansion of Internet Domains Would Go Better At A Slower Pace at Forbes
12:01AM  New Alzheimer's Research Throws Cold Water on Biogen's Recent Breakthrough
Mar-23-15 01:31PM  Pharmacyclics chief to receive $3.6bn from takeover at Financial Times
12:08PM  Cancer Therapy Stock Advaxis Will Benefit From IPO From Rival Aduro at TheStreet
10:06AM  Rationale for the PharmacyclicsAbbVie Merger
08:50AM  Cramer's stocks to watch: Amazing biotech
07:00AM  5 Big Stocks That Want to Pay You More in 2015: Dividend Preview at TheStreet
Mar-22-15 09:44AM  DURECT Corporation (DRRX): First Eagle Raises Its Stake; See Investors Other Healthcare Picks at Insider Monkey
Mar-20-15 11:30PM  Fed Still Playing a Waiting Game at
06:20PM  J&J's Janssen scores partial victory in second Risperdal trial
02:13PM  Biogen shares soar on optimistic Alzheimer's drug study data
12:29PM  Biogen, Alzheimer's and the Biotech Mania (Is It a Bubble?) at TheStreet
11:45AM  Biogen Soars as Alzheimer's Drug Slows Disease in Trial
07:41AM  Biogen releases Alzheimer's drug data
05:40AM  Biogen Drug Could Inspire New Hope For Alzheimer's Treatments at Forbes
05:35AM  Biogen Alzheimers Drug Slows Progression of Disease in Trial at Bloomberg
Mar-19-15 09:00PM  MLS, U.S. Soccer Sign Partnership With Johnson & Johnson at Bloomberg
02:57PM  The Makers Of ZYRTEC┬« Partner With Gilt City To Address The Beauty And Fashion Challenges Of Allergy Season at noodls
12:55PM  Moment of truth for Biogen's big Alzheimer's bet at CNBC
12:30PM  Apple joins Dow, symbolic of techs rising influence in U.S. economy at Silicon Beat
08:48AM  Janssen Acquires XO1 Limited at noodls
08:12AM  The charity that matches surplus medicine with acute need at Financial Times
Mar-18-15 09:05PM  Understanding Johnson & Johnsons Ownership Structure
05:05PM  Where Does Johnson & Johnson Stand in the Industry?
11:05AM  What Risks Does Johnson & Johnson Face?
08:16AM  FDA panel to discuss Ebola vaccine development in May Reuters
Mar-17-15 05:05PM  Understanding Johnson & Johnsons Growth Strategies
04:41PM  Apple still buyback king as repurchases overall slow down at MarketWatch
04:20PM  Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
04:01PM  The 4 Stocks That Sank the Dow on Tuesday at 24/7 Wall St.
01:10PM  Johnson & Johnson to Host Investor Conference Call on First-Quarter Results at noodls
01:06PM  Johnson & Johnson Invested in Research and Development
11:35AM  Kentucky joins lawsuit against Omnicare, claiming billions in losses at
11:30AM  A hidden bear market in Dow threatens all stocks at CNBC
11:26AM  Johnson & Johnson to Host Investor Conference Call on First-Quarter Results PR Newswire
10:52AM  Why These Could Be 2015's 10-Best Pharma Stocks at Investopedia
10:30AM  Merck Reports Encouraging Data from Cardiovascular Study - Analyst Blog
08:00AM  Hedge Funds Favorite Dividend Aristocrats at Insider Monkey
07:08AM  Phase 3 Study with IMBRUVICA┬« (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression at noodls
07:08AM  Johnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally at noodls
07:00AM  The Ultimate Stock-Pickers Top 10 Dividend Stocks at Morningstar
04:15AM  Johnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally PR Newswire
04:00AM  Dementia drug research aided by $100 mln venture capital fund
02:05AM  Johnson & Johnsons Gross Margin Increased
12:17AM  [$$] Warning Prompts Shift In Surgeries on Women at The Wall Street Journal
Mar-16-15 08:20PM  Warning Prompts Shift In Surgeries on Women at The Wall Street Journal
08:16PM  Dementia research boosted by $100m venture capital fund at Financial Times
05:08PM  Pharmacyclics cancer drug successful as combination therapy - independent panel Reuters
03:42PM  FDA panel recommends unblinding study after Imbruvica shows clear benefit Reuters
03:06PM  What Were Johnson & Johnsons Outstanding Expenses?
02:01PM  March Madness: ExxonMobil vs. Chevron
12:52PM  Health Care ETFs Remain Sturdy ETF Trends
11:05AM  Johnson & Johnsons Revenue Stream Increased in 2014
11:00AM  Valeant Pharmaceuticals Poised To Win Bidding War For Salix With $173 A Share Cash Deal at Forbes
08:11AM  Ebola booster vaccine trial to combine GSK, Emergent Bio shots
01:00AM  Dividend Aristocrats: 2 To Buy, 2 To Avoid
Mar-13-15 05:42PM  5 reasons you should be excited about the 'Star Wars: Episode VIII' director
05:06PM  A Snapshot of Johnson & Johnsons Consumer Segment
03:40PM  IMS CEOs $25.9 Million Pay Tops Biggest Health Companies at Bloomberg
03:27PM  Why biotech investors may be hurting innovation at CNBC
11:30AM  McNeil sues GlaxoSmithKline over allergy medicine ad at
Mar-12-15 07:05PM  Exploring Johnson & Johnsons Pharmaceuticals Segment
06:35PM  Johnson & Johnson sues Glaxo over allergy ads as spring nears Reuters
04:09PM  The amazing portfolio that costs less than an iPad at MarketWatch
03:06PM  Johnson & Johnsons Global Business Strategy Promotes Growth
11:06AM  Analyzing Johnson & Johnsons Three Main Business Segments
09:37AM  Billionaire Ken Fishers Top Long-Term Picks: Pfizer Inc., Visa Inc., and More at Insider Monkey
07:14AM  CVS: Copycat drugs may bring price cuts of 40-50% at CNBC
05:29AM  Black and blue chips pummeled by strengthening dollar
Mar-11-15 04:30PM  Johnson & Johnson: A Leading Pharmaceuticals Company
03:31PM  Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fasolo PeterVP, Global Human ResourcesMar 05Option Exercise65.37115,3077,537,619147,895Mar 09 05:14 PM
Fasolo PeterVP, Global Human ResourcesMar 05Sale102.40115,30711,807,86332,588Mar 09 05:14 PM
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM